167 related articles for article (PubMed ID: 28465589)
21. Upregulation of the N-formyl Peptide receptors in scleroderma fibroblasts fosters the switch to myofibroblasts.
Rossi FW; Napolitano F; Pesapane A; Mascolo M; Staibano S; Matucci-Cerinic M; Guiducci S; Ragno P; di Spigna G; Postiglione L; Marone G; Montuori N; de Paulis A
J Immunol; 2015 Jun; 194(11):5161-73. PubMed ID: 25917089
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo.
Sato S; Kopitz C; Grismayer B; Beaufort N; Reuning U; Schmitt M; Luther T; Kotzsch M; Krüger A; Magdolen V
Breast Cancer Res Treat; 2011 Jun; 127(3):649-57. PubMed ID: 20635136
[TBL] [Abstract][Full Text] [Related]
23. The Expression of Formyl Peptide Receptor 1 is Correlated with Tumor Invasion of Human Colorectal Cancer.
Li SQ; Su N; Gong P; Zhang HB; Liu J; Wang D; Sun YP; Zhang Y; Qian F; Zhao B; Yu Y; Ye RD
Sci Rep; 2017 Jul; 7(1):5918. PubMed ID: 28724995
[TBL] [Abstract][Full Text] [Related]
24. Cyclization of the urokinase receptor-derived ser-arg-ser-arg-tyr Peptide generates a potent inhibitor of trans-endothelial migration of monocytes.
Yousif AM; Minopoli M; Bifulco K; Ingangi V; Di Carluccio G; Merlino F; Motti ML; Grieco P; Carriero MV
PLoS One; 2015; 10(5):e0126172. PubMed ID: 25938482
[TBL] [Abstract][Full Text] [Related]
25. UPARANT: a urokinase receptor-derived peptide inhibitor of VEGF-driven angiogenesis with enhanced stability and in vitro and in vivo potency.
Carriero MV; Bifulco K; Minopoli M; Lista L; Maglio O; Mele L; Di Carluccio G; De Rosa M; Pavone V
Mol Cancer Ther; 2014 May; 13(5):1092-104. PubMed ID: 24705350
[TBL] [Abstract][Full Text] [Related]
26. Cathepsin B and uPAR knockdown inhibits tumor-induced angiogenesis by modulating VEGF expression in glioma.
Malla RR; Gopinath S; Gondi CS; Alapati K; Dinh DH; Gujrati M; Rao JS
Cancer Gene Ther; 2011 Jun; 18(6):419-34. PubMed ID: 21394106
[TBL] [Abstract][Full Text] [Related]
27. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
[TBL] [Abstract][Full Text] [Related]
28. Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth.
Lakka SS; Gondi CS; Yanamandra N; Dinh DH; Olivero WC; Gujrati M; Rao JS
Cancer Res; 2003 May; 63(10):2454-61. PubMed ID: 12750266
[TBL] [Abstract][Full Text] [Related]
29. An urokinase receptor antagonist that inhibits cell migration by blocking the formyl peptide receptor.
Bifulco K; Longanesi-Cattani I; Gargiulo L; Maglio O; Cataldi M; De Rosa M; Stoppelli MP; Pavone V; Carriero MV
FEBS Lett; 2008 Apr; 582(7):1141-6. PubMed ID: 18339322
[TBL] [Abstract][Full Text] [Related]
30. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
31. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
[TBL] [Abstract][Full Text] [Related]
32. ECRG2 regulates ECM degradation and uPAR/FPRL1 pathway contributing cell invasion/migration.
Cheng X; Lu SH; Cui Y
Cancer Lett; 2010 Apr; 290(1):87-95. PubMed ID: 19796867
[TBL] [Abstract][Full Text] [Related]
33. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer.
Shin VY; Wu WK; Chu KM; Wong HP; Lam EK; Tai EK; Koo MW; Cho CH
Mol Cancer Res; 2005 Nov; 3(11):607-15. PubMed ID: 16317086
[TBL] [Abstract][Full Text] [Related]
34. Role of formic receptors in soluble urokinase receptor-induced human vascular smooth muscle migration.
Duru EA; Fu Y; Davies MG
J Surg Res; 2015 May; 195(2):396-405. PubMed ID: 25758338
[TBL] [Abstract][Full Text] [Related]
35. The role of formyl peptide receptor 1 (FPR1) in neuroblastoma tumorigenesis.
Snapkov I; Öqvist CO; Figenschau Y; Kogner P; Johnsen JI; Sveinbjørnsson B
BMC Cancer; 2016 Jul; 16():490. PubMed ID: 27432059
[TBL] [Abstract][Full Text] [Related]
36. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
37. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
38. The YSNSG cyclopeptide derived from tumstatin inhibits tumor angiogenesis by down-regulating endothelial cell migration.
Thevenard J; Ramont L; Devy J; Brassart B; Dupont-Deshorgue A; Floquet N; Schneider L; Ouchani F; Terryn C; Maquart FX; Monboisse JC; Brassart-Pasco S
Int J Cancer; 2010 Mar; 126(5):1055-66. PubMed ID: 19551865
[TBL] [Abstract][Full Text] [Related]
39. Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver.
Van Buren G; Gray MJ; Dallas NA; Xia L; Lim SJ; Fan F; Mazar AP; Ellis LM
Cancer; 2009 Jul; 115(14):3360-8. PubMed ID: 19484792
[TBL] [Abstract][Full Text] [Related]
40. In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.
Jing Y; Bejarano MT; Zaias J; Merchan JR
Breast Cancer Res Treat; 2015 Jan; 149(1):99-108. PubMed ID: 25519042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
